92 related articles for article (PubMed ID: 17604618)
41. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
[TBL] [Abstract][Full Text] [Related]
42. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
43. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
44. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
45. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Hwang ES; Hyslop T; Hendrix LH; Duong S; Bedrosian I; Price E; Caudle A; Hieken T; Guenther J; Hudis CA; Winer E; Lyss AP; Dickson-Witmer D; Hoefer R; Ollila DW; Hardman T; Marks J; Chen YY; Krings G; Esserman L; Hylton N
J Clin Oncol; 2020 Apr; 38(12):1284-1292. PubMed ID: 32125937
[TBL] [Abstract][Full Text] [Related]
46. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Chen YY; DeVries S; Anderson J; Lessing J; Swain R; Chin K; Shim V; Esserman LJ; Waldman FM; Hwang ES
BMC Cancer; 2009 Aug; 9():285. PubMed ID: 19689789
[TBL] [Abstract][Full Text] [Related]
47. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Generali D; Buffa FM; Deb S; Cummings M; Reid LE; Taylor M; Andreis D; Allevi G; Ferrero G; Byrne D; Martinotti M; Bottini A; Harris AL; Lakhani SR; Fox SB
Br J Cancer; 2014 Jul; 111(1):46-54. PubMed ID: 24874483
[TBL] [Abstract][Full Text] [Related]
48. Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Juraskova I; Butow P; Lopez A; Seccombe M; Coates A; Boyle F; McCarthy N; Reaby L; Forbes JF
Health Expect; 2008 Sep; 11(3):252-62. PubMed ID: 18816321
[TBL] [Abstract][Full Text] [Related]
49. Studies of epidermal growth factor receptor inhibition in breast cancer.
Bundred NJ; Chan K; Anderson NG
Endocr Relat Cancer; 2001 Sep; 8(3):183-9. PubMed ID: 11566609
[TBL] [Abstract][Full Text] [Related]
50. Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Bundred NJ; Barnes NL
Br J Cancer; 2005 Aug; 93 Suppl 1(Suppl 1):S10-5. PubMed ID: 16100520
[TBL] [Abstract][Full Text] [Related]
51. Endocrine therapy in DCIS: how do we proceed?
Dixon JM; Jane Macaskill E
Breast J; 2012; 18(4):295-8. PubMed ID: 22759092
[No Abstract] [Full Text] [Related]
52. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
Altundag K
J BUON; 2018; 23(3):835. PubMed ID: 30003760
[No Abstract] [Full Text] [Related]
53. Cognitive effects of aromatase inhibitor therapy in peripubertal boys.
Hero M; Maury S; Luotoniemi E; Service E; Dunkel L
Eur J Endocrinol; 2010 Jul; 163(1):149-55. PubMed ID: 20421333
[TBL] [Abstract][Full Text] [Related]
54. Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy.
Klemi P; Alanen K; Hietanen S; Grénman S; Varpula M; Salmi T
Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1155-8. PubMed ID: 14607040
[TBL] [Abstract][Full Text] [Related]
55. Treating breast precancer.
O'Shaughnessy JA
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S74-9. PubMed ID: 11970754
[TBL] [Abstract][Full Text] [Related]
56. Effect of 3α-dihydroprogesterone and 5α-dihydroprogesterone on DCIS cells and possible impact for postmenopausal women.
Sourouni M; Götte M; Kiesel L; von Wahlde MK
Climacteric; 2023 Jun; 26(3):275-283. PubMed ID: 36880551
[TBL] [Abstract][Full Text] [Related]
57. Benefit of tamoxifen in estrogen receptor positive DCIS of the breast.
Fausto P; Barni S
Gland Surg; 2012 May; 1(1):3-4. PubMed ID: 25083418
[No Abstract] [Full Text] [Related]
58. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Chlebowski RT; Col N
Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
[TBL] [Abstract][Full Text] [Related]
59. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
[TBL] [Abstract][Full Text] [Related]
60. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Takagi K; Ishida T; Miki Y; Hirakawa H; Kakugawa Y; Amano G; Ebata A; Mori N; Nakamura Y; Watanabe M; Amari M; Ohuchi N; Sasano H; Suzuki T
Br J Cancer; 2013 Jul; 109(1):100-8. PubMed ID: 23756858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
